The debate surfaced genuine tension between a fundamentally improving franchise and a deteriorating chart. On the bull side, LMT's Q2 2026 print was strong in absolute terms (revenue +10.5% YoY, deferred revenue +23% YoY at $12.15B, EPS $7.94), the Patriot tripling contract provides multi-year revenue visibility, and the forward PEG of ~0.78 isn't demanding. These are real structural strengths I don't dismiss. However, the bear dismantled the magnitude of the bull's case in ways I found compelling: the Q2 2026 operating margin of 12.4% is only 20bps above Q3 2025's 12.2% — meaning the "spectacular" YoY comparison is partially a low-base artifact from Q2 2025's program charges, not pure operational outperformance. The Patriot ramp also creates near-term headwinds (capex spike, working capital ballooning to $4.59B from -$366M YoY) that the bull glossed over. Most damning is the chart: LMT just got rejected at $606.61 three weeks ago, is now below the 50 SMA, 200 SMA, 10 EMA, and lower Bollinger Band simultaneously, with the MACD histogram collapsing -25.7 points and ATR expanding from $12-13 to $14+. That is confirmed distribution, not noise. Capital is rotating from LMT bellwether into small-cap defense names, which de-rates the multiple regardless of operational improvement. The risk/reward math is decisive: -23% downside to the bull's $497 stop against +13% upside to $600 yields roughly 1:0.55 — the bear is right to call this an asymmetric entry for sellers, not buyers. Sentiment at 6.5/10 "Mildly Bullish" with bullish narrative already out there means the marginal buyer is largely in. I cannot commit to Buy because technicals and capital flow disagree, and I cannot go Underweight because the forward earnings power and deferred revenue visibility are genuine. The evidence points to Hold with a defensive lean — fundamentals intact, but timing and price are wrong for new longs.

POSITION STRATEGY: For existing holders: Maintain core position, do not add. Quality franchise with $12B+ in deferred revenue and ~21% forward EPS growth supports holding the position, but the 6.5/10 sentiment reading with technical breakdown suggests this is not the moment to overweight. If already at target weight, sit tight; if overweight by 5%+ versus benchmark, consider trimming 10-25% of the position into any relief bounce toward $549-$557 (the 50/200 SMA cluster) rather than chasing exits into the breakdown.

RISK MANAGEMENT: Tighten risk management immediately. Set hard stops at $520 close (intraday weakness below this is noise; a closing break signals a likely retest of the April $497 low). The widening ATR of $14+ means $520 is roughly half-ATR below current — a trader's stop, not an investor's. A confirmed close below $520 → exit remaining position ahead of a likely $497 test.

ENTRY STRATEGY: Buyers (new capital): Stand aside. The risk/reward at current levels is broken: ~$74 of demonstrated overhead supply from the August 12 rejection at $606.61, and ~$34 of downside to $497. Do not initiate here. Two valid re-entry triggers: Bullish trigger — Confirmed reversal, a close above $557 (200 SMA) on volume with RSI curling up through 40 and MACD histogram turning positive. Scale into position on pullbacks to $549-$557. Patience trigger — Successful retest and hold of $497 with positive momentum divergence (RSI making higher low while price makes lower low). Build position with stops below $484, targeting $549 first, then $600.

HEDGING: Hedge existing exposure if position is large. With ATR expanding and a clear technical breakdown in motion, protective puts (3-6 month, strike near $510-$520) are reasonable insurance for holders with concentrated LMT exposure. The cost is meaningful but cheaper than waiting to react to a $497 retest.

CATALYST MONITORING: Watch the catalysts that matter, not the ones that headline. The Pentagon budget continuing resolution (Q4 2026), F-35 LRIP contract decisions, and any formal Patriot production milestone disclosures are higher-information triggers than broad sentiment surveys. Position adjustments should be driven by these, not by price action alone.

RE-EVALUATION: Re-evaluate in 4-6 weeks. If by mid-October 2026 the stock has either reclaimed $549 with improving momentum OR defended $497 with a basing pattern, the recommendation set can shift toward Overweight. Until then, the disciplined stance is Hold with defensive lean.

The investment plan presents a credible Hold case that I will not override. On the fundamental side, LMT's Q2 2026 print (revenue +10.5% YoY, deferred revenue $12.15B, EPS $7.94), the Patriot tripling contract, and a forward PEG near 0.78 confirm the franchise's structural quality and multi-year earnings visibility. However, the bear case on timing and price is decisive: LMT was rejected at $606.61 three weeks ago and is now simultaneously below the 50 SMA, 200 SMA, 10 EMA, and lower Bollinger Band, with the MACD histogram collapsing -25.7 points and ATR expanding from $12-13 to $14+ — confirmed distribution, not noise. Capital is rotating out of defense bellwethers into small-cap defense names, and the risk/reward is asymmetric to sellers (-23% to the $497 bull stop vs +13% to $600, roughly 1:0.55). With sentiment already 6.5/10 "Mildly Bullish" and a bullish narrative in the market, the marginal buyer is largely in. I will not Buy into confirmed breakdown with broken risk/reward, and I will not Sell given intact fundamentals and $12B+ deferred revenue visibility. Hold is the correct stance, with a defensive lean and tightened risk management.

Stop loss: $520.00

Sizing: Maintain current weight; do not add. If overweight by 5%+ versus benchmark, consider trimming 10-25% into any relief bounce toward $549-$557 (the 50/200 SMA cluster). For new capital: stand aside until a confirmed close above $557 with positive MACD histogram, or a successful retest and hold of $497 with positive momentum divergence.